Yongliang "Steve" Sun
About Yongliang "Steve" Sun
Yongliang 'Steve' Sun is the Associate Director of Translational Sciences and Diagnostics at Bristol Myers Squibb, with a background in immunology and extensive experience in clinical biomarker technologies.
Title at Bristol Myers Squibb
Yongliang 'Steve' Sun holds the position of Associate Director, Translational Sciences And Diagnostics at Bristol Myers Squibb. Located in Princeton, New Jersey, United States, Sun specializes in immunotherapy, immuno-oncology, autoimmune diseases, precision medicine, and clinical biomarker technologies, contributing significantly to the company's mission in translational sciences.
Education and Expertise
Yongliang 'Steve' Sun has a rich educational background in immunology and infectious diseases. He earned his Doctor of Medicine (MD) degree from Zhejiang University and later pursued further studies in immunology at the University of Toronto, where he also achieved a post-doctoral qualification. His extensive education has equipped him with significant expertise in fields crucial to translational sciences and diagnostics.
Professional Background and Previous Positions
Before joining Bristol Myers Squibb, Yongliang 'Steve' Sun served in several prominent roles at esteemed pharmaceutical companies. At Pfizer, he was a Senior Scientist in the Biomarkers/Biomeasures group within the Pharmacokinetics, Dynamics & Metabolism department from 2013 to 2015 in Groton, Connecticut. Prior to that, he worked at Roche as an Associate Principal Scientist focusing on Inflammation/Immunology Discovery from 2009 to 2012 in Nutley, New Jersey. His career also includes a significant nine-year tenure as Research Scientist at Merck, Schering-Plough Research Institute, specializing in Immunology/Inflammation Discovery in Kenilworth, New Jersey.
Research Contributions
Yongliang 'Steve' Sun has made substantial contributions to the field of translational sciences and diagnostics. He has developed and validated novel flow cytometry-based clinical biomarker assays. Moreover, his work has been critical in the approvals of key drugs such as OPDIVO®, OPDUALAG®, YERVOY®, ORENCIA®, and BESPONSA®. His research is published in several peer-reviewed journals, further underpinning his impact on the industry.
Conference Presentations and Industry Engagement
Yongliang 'Steve' Sun is an active participant in the scientific community, having been an invited speaker and panelist at major conferences like AAPS PharmSci360, WRIB, and CYTO. His presentations often focus on clinical biomarker technologies and their applications in precision medicine and immuno-oncology, among other subjects, highlighting his role as a thought leader in his field.